Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $111
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained its Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raised the price target from $109 to $111.
May 31, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has maintained its Buy rating on Ultragenyx Pharmaceutical and raised the price target from $109 to $111.
The Buy rating and increased price target from a reputable analyst firm like Canaccord Genuity is likely to positively influence investor sentiment and drive short-term price appreciation for Ultragenyx Pharmaceutical.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100